https://www.biospace.com/employer/44933/astrazeneca AstraZeneca en-US Tue, 31 Mar 2020 14:30:47 GMT https://www.biospace.com/non-covid-19-pharma-news-roundup Alex Keown The following is a roundup of some of this week's non-coronavirus biopharma news. Tue, 31 Mar 2020 14:30:47 GMT https://www.biospace.com/non-covid-19-pharma-news-roundup https://www.biospace.com/astrazeneca-outlines-antibody-work-targeting-covid-19 Mark Terry AstraZeneca made an announcement describing its internal and partnering efforts to battle COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Wed, 08 Apr 2020 14:07:38 GMT https://www.biospace.com/astrazeneca-outlines-antibody-work-targeting-covid-19 https://www.biospace.com/astrazeneca-halts-phase-iii-farxiga-trial-in-ckd-early-due-to-overwhelming-efficacy Alex Keown AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease. Mon, 30 Mar 2020 12:58:19 GMT https://www.biospace.com/astrazeneca-halts-phase-iii-farxiga-trial-in-ckd-early-due-to-overwhelming-efficacy https://www.biospace.com/clinical-catch-up-april-6-10 Mark Terry It was a very busy week for clinical trial news. Here’s a look. Fri, 10 Apr 2020 14:34:59 GMT https://www.biospace.com/clinical-catch-up-april-6-10 https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-15 BioSpace Editorial Staff Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020. Tue, 14 Jul 2020 16:46:02 GMT https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-15 https://www.biospace.com/astrazeneca-s-early-covid-19-vaccine-data-show-a-double-defense-against-the-virus Alex Keown Phase I data from the COVID-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe. Thu, 16 Jul 2020 13:00:23 GMT https://www.biospace.com/astrazeneca-s-early-covid-19-vaccine-data-show-a-double-defense-against-the-virus https://www.biospace.com/astrazeneca-s-brilinta-decreases-decreases-risk-of-stroke-and-death Mark Terry AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin. Thu, 16 Jul 2020 12:17:58 GMT https://www.biospace.com/astrazeneca-s-brilinta-decreases-decreases-risk-of-stroke-and-death https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-17 BioSpace Editorial Staff Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020. Thu, 16 Jul 2020 15:06:18 GMT https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-17 https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-20 BioSpace Editorial Staff Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020. Mon, 20 Jul 2020 12:44:10 GMT https://www.biospace.com/biopharma-update-on-the-novel-coronavirus-july-20 https://www.biospace.com/astrazeneca-oxford-post-positive-phase-i-data-for-covid-19-vaccine-candidate Alex Keown AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed. Mon, 20 Jul 2020 14:47:59 GMT https://www.biospace.com/astrazeneca-oxford-post-positive-phase-i-data-for-covid-19-vaccine-candidate